Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EREMISS: Regorafenib Maintenance in Soft Tissue Sarcoma
NCT03793361Phase 2Completed
- Sponsor
- Centre Oscar Lambret
- Start
- May 2019
- Primary completion
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in soft tissue sarcoma (STS) comparing Regorafenib with Placebo (2 arms). Primary endpoint: Progression-Free Survival up to 12 months. Started May 2019; status: completed.
02
Drugs
regorafenib
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT03793361.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03793361.